Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.

B. E. Hillner, Thomas J Smith

Research output: Contribution to journalArticle

Abstract

The 1992 metaanalysis of adjuvant therapies after surgery in early breast cancer summarizes the most extensively studied of all cancer treatments via randomized controlled trials. This study found overall benefits with use of adjuvant therapies, and their expanded use outside the clinical trial setting was assumed to be effective and implied to be cost effective. Thus, the primary remaining questions are which form of adjuvant therapy to use and how to identify which patients are unlikely to benefit. In British Columbia, the effectiveness of adjuvant therapy outside the clinical trial setting was reassuringly similar to the metaanalysis efficacy. Our decision analysis model of hypothetical cohorts of women with early breast cancer confirmed that the efficacy of adjuvant treatment is the primary determinate of its incremental cost effectiveness. Future cost-effectiveness and quality of life assessments should move from hypothetical cohorts assessed via models to prospective data collected within clinical trials or integrated health delivery system.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalOncology
Volume9
Issue number11 Suppl
StatePublished - Nov 1995
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Breast Neoplasms
Clinical Trials
Integrated Delivery of Health Care
Therapeutics
British Columbia
Decision Support Techniques
Randomized Controlled Trials
Quality of Life
Costs and Cost Analysis
Health
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. / Hillner, B. E.; Smith, Thomas J.

In: Oncology, Vol. 9, No. 11 Suppl, 11.1995, p. 129-134.

Research output: Contribution to journalArticle

@article{f7dec27e175d433f90f3f970d2e7cf2b,
title = "Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.",
abstract = "The 1992 metaanalysis of adjuvant therapies after surgery in early breast cancer summarizes the most extensively studied of all cancer treatments via randomized controlled trials. This study found overall benefits with use of adjuvant therapies, and their expanded use outside the clinical trial setting was assumed to be effective and implied to be cost effective. Thus, the primary remaining questions are which form of adjuvant therapy to use and how to identify which patients are unlikely to benefit. In British Columbia, the effectiveness of adjuvant therapy outside the clinical trial setting was reassuringly similar to the metaanalysis efficacy. Our decision analysis model of hypothetical cohorts of women with early breast cancer confirmed that the efficacy of adjuvant treatment is the primary determinate of its incremental cost effectiveness. Future cost-effectiveness and quality of life assessments should move from hypothetical cohorts assessed via models to prospective data collected within clinical trials or integrated health delivery system.",
author = "Hillner, {B. E.} and Smith, {Thomas J}",
year = "1995",
month = "11",
language = "English (US)",
volume = "9",
pages = "129--134",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 Suppl",

}

TY - JOUR

T1 - Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.

AU - Hillner, B. E.

AU - Smith, Thomas J

PY - 1995/11

Y1 - 1995/11

N2 - The 1992 metaanalysis of adjuvant therapies after surgery in early breast cancer summarizes the most extensively studied of all cancer treatments via randomized controlled trials. This study found overall benefits with use of adjuvant therapies, and their expanded use outside the clinical trial setting was assumed to be effective and implied to be cost effective. Thus, the primary remaining questions are which form of adjuvant therapy to use and how to identify which patients are unlikely to benefit. In British Columbia, the effectiveness of adjuvant therapy outside the clinical trial setting was reassuringly similar to the metaanalysis efficacy. Our decision analysis model of hypothetical cohorts of women with early breast cancer confirmed that the efficacy of adjuvant treatment is the primary determinate of its incremental cost effectiveness. Future cost-effectiveness and quality of life assessments should move from hypothetical cohorts assessed via models to prospective data collected within clinical trials or integrated health delivery system.

AB - The 1992 metaanalysis of adjuvant therapies after surgery in early breast cancer summarizes the most extensively studied of all cancer treatments via randomized controlled trials. This study found overall benefits with use of adjuvant therapies, and their expanded use outside the clinical trial setting was assumed to be effective and implied to be cost effective. Thus, the primary remaining questions are which form of adjuvant therapy to use and how to identify which patients are unlikely to benefit. In British Columbia, the effectiveness of adjuvant therapy outside the clinical trial setting was reassuringly similar to the metaanalysis efficacy. Our decision analysis model of hypothetical cohorts of women with early breast cancer confirmed that the efficacy of adjuvant treatment is the primary determinate of its incremental cost effectiveness. Future cost-effectiveness and quality of life assessments should move from hypothetical cohorts assessed via models to prospective data collected within clinical trials or integrated health delivery system.

UR - http://www.scopus.com/inward/record.url?scp=0029400040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029400040&partnerID=8YFLogxK

M3 - Article

C2 - 8608043

AN - SCOPUS:0029400040

VL - 9

SP - 129

EP - 134

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11 Suppl

ER -